← Back to Search

Imaging

Non-Invasive Retinal Assessment for Retinal Disease

N/A
Recruiting
Led By Randy H Kardon, MD, PhD
Research Sponsored by Randy Kardon
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Defined structural defect to include those with Ischemic optic neuropathy, branch retinal artery occlusion (BRAO), hemianopia or visual field defect that respects the vertical meridian, inherited mitochondrial optic neuropathies such as Leber's and Dominant Optic Neuropathy, other retinopathies or optic neuropathies.
Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are okay. Any abnormalities of the retina or optic nerve that could affect metabolism of the retina outside of normal.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at a new way to measure damage to the eye. Images of the retina are compared to other tests of visual function to see if this new method is effective.

Who is the study for?
This trial is for people with certain eye conditions like Ischemic Optic Neuropathy, Retinal Artery Occlusion, and Leber's Optic Atrophy. Participants should have had a normal eye exam in the last two years and can't have severe cataracts or other issues that would affect retinal imaging.
What is being tested?
The study is testing LSFG-NAVI, a new non-invasive technology to examine the retina's structure and function. It aims to identify abnormal areas by comparing this method with other visual tests in subjects with inner or outer retinal defects.
What are the potential side effects?
Since LSFG-NAVI is a diagnostic tool rather than a treatment, it typically doesn't involve side effects like medications do. However, there might be discomfort from bright lights or sitting still during the imaging process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a specific eye condition affecting my vision.
Select...
I have mild cataracts or clear vision that doesn't affect detailed eye scans.
Select...
I have been diagnosed with AZOOR or similar vision loss conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ocular Blood Flow

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Laser Speckle Blood Flow GroupExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Randy KardonLead Sponsor
3 Previous Clinical Trials
621 Total Patients Enrolled
Randy H Kardon, MD, PhDPrincipal InvestigatorUniversity of Iowa Department of Ophthalmology

Media Library

LSFG-NAVI (Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT03475173 — N/A
Ischemic Optic Neuropathy Research Study Groups: Laser Speckle Blood Flow Group
Ischemic Optic Neuropathy Clinical Trial 2023: LSFG-NAVI Highlights & Side Effects. Trial Name: NCT03475173 — N/A
LSFG-NAVI (Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03475173 — N/A
Ischemic Optic Neuropathy Patient Testimony for trial: Trial Name: NCT03475173 — N/A
~180 spots leftby Jan 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top